Furthermore, we investigated here a population of AD patients with established abnormal amyloid and tau protein levels in the CSF, reduced whole hippocampal volume and reduced cerebral glucose metabolism in brain areas that are pathognomonic of AD. The gene discussed is MAPT; the disease is Alzheimer disease.